GnRH Receptor Antagonist Mono- And Combination Therapy With E2/NETA Add-Back - Pharmacodynamics And Safety Of OBE2109.

Conclusions: OBE2109 promptly lowers E2 levels, add-back may be required to prevent adverse bone impact in subjects treated at 200mg and in some subjects at 100mg. Our results provide a basis for OBE2109 regimen selection to treat sex-hormone-dependent diseases. PMID: 29216361 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29216361?dopt=Abstract

Source: The Journal of Clinical Endocrinology and Metabolism - December 4, 2017 Category: Endocrinology Authors: Pohl O, Marchand L, Fawkes N, Gotteland JP, Loumaye E Tags: J Clin Endocrinol Metab Source Type: research